Skip to content

Utility of Sodium Lactate Infusion During Septic Shock

Utility of Sodium Lactate Infusion During Septic Shock: Pilot Study

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03528213
Acronym
ULIS1
Enrollment
59
Registered
2018-05-17
Start date
2019-10-04
Completion date
2023-02-21
Last updated
2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

sepsis, fluid balance, metabolism, ischemia-reperfusion, treatment

Brief summary

ULIS-1 is an open-label pilot study concerning utility of molar sodium lactate in fluid balance in septic shock patients

Detailed description

ULIS-1 consists in three arms of treatment during the first 24hrs of septic shock treatment. * normal saline * sodium lactate 2.5ml/kg in 60min then * either 0.25 or 0.5ml/kg/h during 24hrs Main criteria is fluid balance at 48hrs

Interventions

DRUGSodium Lactate light dose

bolus 2.5ml/kg then 0.25ml/kg/h

DRUGSodium Lactate high dose

bolus 2.5ml/kg then 0.5ml/kg/h

DRUGNormal saline

normal saline at physician discretion

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

bolus then continuous infusion of molar sodium lactate (2 doses) or normal saline

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Presence of septic shock * requiring vascular filling within 12 hours after introduction of Noradrenaline. Septic shock is defined as sepsis with persistent hypotension requiring the administration of vasopressors to maintain RTE \> 65mmHg. * social insurance

Exclusion criteria

* pregnancy * cardiac arrest * more than 50ml/kg of fluid loading * chronic renal failure with chronic hemodialysis or the investigators estimate a need for renal replacement therapy in the following 24hrs * child C or acute liver failure with PT\<40% (unless AVK) * plasmatic sodium \<120 or \>145mmol/l * metabolic alkalosis with pH\>7.45

Design outcomes

Primary

MeasureTime frameDescription
fluid balanceat 48 hoursfluid balance

Secondary

MeasureTime frame
SOFA (Sequential Organ Failure Assessment)Day 1, Day 2, Day 3, Day 7
death in Intensive Care Unit (ICU)Day 90
number of patients deadDay 28
death in hospitalDay 90
catecholamines free daysDay 28
ventilator free daysDay 28
fluid balance at day 7Day 7
new kidney failureDay 28
nosocomial infectionsday 90
hypernatremiaDay 2
hypokaliemiaDay 2
metabolic alkalosisday 2
hemodynamic effects assessed by the PICCO® monitoring systemat 48 hours
renal replacement therapy free daysDay 28

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026